|
1
|
Aktas G: A comprehensive review on
rational and effective treatment strategies against an invisible
enemy; SARS Cov-2 infection. Exp Biomed Res. 3:293–311. 2020.
View Article : Google Scholar
|
|
2
|
Wu Z and McGoogan JM: Characteristics of
and Important Lessons From the Coronavirus Disease 2019 (COVID-19)
Outbreak in China: Summary of a Report of 72 314 Cases From the
Chinese Center for Disease Control and Prevention. JAMA.
323:1239–1242. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aktas G, Balci B, Yilmaz S, Bardak H and
Duman TT: Characteristics of Covid-19 infection with the original
SARS-Cov-2 virus and other variants: A comparative review. J Bionic
Mem. 2:96–112. 2022.
|
|
4
|
Ceasovschih A, Sorodoc V, Shor A, Haliga
RE, Roth L, Lionte C, Onofrei Aursulesei V, Sirbu O, Culis N,
Shapieva A, et al: Distinct features of vascular diseases in
COVID-19. J Inflamm Res. 16:2783–2800. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khalid A, Ali Jaffar M, Khan T, Abbas Lail
R, Ali S, Aktas G, Waris A, Javaid A, Ijaz N and Muhammad N:
Hematological and biochemical parameters as diagnostic and
prognostic markers in SARS-COV-2 infected patients of Pakistan: A
retrospective comparative analysis. Hematology. 26:529–542. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aktas G: Hematological predictors of novel
Coronavirus infection. Rev Assoc Med Bras (1992). 67 (Suppl
1):S1–S2. 2021. View Article : Google Scholar
|
|
7
|
Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J
and Peiffer-Smadja N: Comparing COVID-19 vaccines for their
characteristics, efficacy and effectiveness against SARS-CoV-2 and
variants of concern: A narrative review. Clin Microbiol Infect.
28:202–221. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng B, Zhao Q, Yang W, Feng P, Xin C,
Ying Y, Yang B, Han B, Zhu J, Zhang M and Li G: Small-molecule
antiviral treatments for COVID-19: A systematic review and network
meta-analysis. Int J Antimicrob Agents. 63:1070962024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saul S and Einav S: Old drugs for a new
virus: Repurposed approaches for combating COVID-19. ACS Infect
Dis. 6:2304–2318. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Crawford KHD, Dingens AS, Eguia R, Wolf
CR, Wilcox N, Logue JK, Shuey K, Casto AM, Fiala B, Wrenn S, et al:
Dynamics of neutralizing antibody titers in the months after severe
acute respiratory syndrome coronavirus 2 infection. J Infect Dis.
223:197–205. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prévost J, Gasser R, Beaudoin-Bussières G,
Richard J, Duerr R, Laumaea A, Anand SP, Goyette G, Benlarbi M,
Ding S, et al: Cross-Sectional Evaluation of Humoral Responses
against SARS-CoV-2 Spike. Cell Rep Med. 1:1001262020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li M, Wang H, Tian L, Pang Z, Yang Q,
Huang T, Fan J, Song L, Tong Y and Fan H: COVID-19 vaccine
development: milestones, lessons and prospects. Signal Transduct
Target Ther. 7:1462022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wakefield TW, Strieter RM, Wilke CA,
Kadell AM, Wrobleski SK, Burdick MD, Schmidt R, Kunkel SL and
Greenfield LJ: Venous thrombosis-associated inflammation and
attenuation with neutralizing antibodies to cytokines and adhesion
molecules. Arterioscler Thromb Vasc Biol. 15:258–268. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cagdas D: Convalescent plasma and
hyperimmune globulin therapy in COVID-19. Expert Rev Clin Immunol.
17:309–316. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang
J, Kong Y, Ren L, Wei Q, Mei H, et al: Effect of convalescent
plasma therapy on time to clinical improvement in patients with
severe and life-threatening COVID-19: A Randomized clinical trial.
JAMA. 324:460–470. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang J, Grubbs G, Lee Y, Golding H and
Khurana S: Impact of convalescent plasma therapy on severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody profile in
coronavirus disease 2019 (COVID-19) Patients. Clin Infect Dis.
74:327–334. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Ma Y, Xu Y, Liu J, Li X, Chen Y,
Chen Y, Xie J, Xiao L, Xiang Z, et al: Resistance of SARS-CoV-2
Omicron variant to convalescent and CoronaVac vaccine plasma. Emerg
Microbes Infect. 11:424–427. 2022.PubMed/NCBI
|
|
18
|
Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin
L, Han Y, Xiong Y, Liu Z, Ruan L and Li T: High-Dose intravenous
immunoglobulin in severe coronavirus disease 2019: A multicenter
retrospective study in China. Front Immunol. 12:6278442021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao W, Liu X, Bai T, Fan H, Hong K, Song
H, Han Y, Lin L, Ruan L and Li T: High-Dose intravenous
immunoglobulin as a therapeutic option for deteriorating patients
with coronavirus disease 2019. Open Forum Infect Dis.
7:ofaa1022020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiang HR, Cheng X, Li Y, Luo WW, Zhang QZ
and Peng WX: Efficacy of IVIG (intravenous immunoglobulin) for
corona virus disease 2019 (COVID-19): A meta-analysis. Int
Immunopharmacol. 96:1077322021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kindgen-Milles D, Feldt T, Jensen BEO,
Dimski T and Brandenburger T: Why the application of IVIG might be
beneficial in patients with COVID-19. Lancet Respir Med.
10:e152022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Breedveld FC: Therapeutic monoclonal
antibodies. Lancet. 355:735–740. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Buss NA, Henderson SJ, McFarlane M,
Shenton JM and de Haan L: Monoclonal antibody therapeutics: History
and future. Curr Opin Pharmacol. 12:615–622. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ren Z, Shen C and Peng J: Status and
developing strategies for neutralizing monoclonal antibody therapy
in the omicron Era of COVID-19. Viruses. 15:12972023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pinto D, Park YJ, Beltramello M, Walls AC,
Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, et
al: Cross-neutralization of SARS-CoV-2 by a human monoclonal
SARS-CoV antibody. Nature. 583:290–295. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hillenbrand M, Esslinger C, Seidenberg J,
Weber M, Zingg A, Townsend C, Eicher B, Rutkauskaite J, Riese P,
Guzman CA, et al: Fast-Track Discovery of SARS-CoV-2-neutralizing
antibodies from human B Cells by direct functional screening.
Viruses. 16:3392024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gottlieb RL, Nirula A, Chen P, Boscia J,
Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al:
Effect of bamlanivimab as monotherapy or in combination with
etesevimab on viral load in patients with mild to moderate
COVID-19: A Randomized clinical trial. JAMA. 325:632–644. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weinreich DM, Sivapalasingam S, Norton T,
Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, et al:
REGN-COV2, a neutralizing antibody cocktail, in outpatients with
Covid-19. N Engl J Med. 384:238–251. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ji Y, Zhang Q, Cheng L, Ge J, Wang R, Fang
M, Mucker EM, Chen P, Ma J, Zhang R, et al: Preclinical
characterization of amubarvimab and romlusevimab, a pair of
non-competing neutralizing monoclonal antibody cocktail, against
SARS-CoV-2. Front Immunol. 13:9804352022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Evering TH, Chew KW, Giganti MJ, Moser C,
Pinilla M, Wohl DA, Currier JS, Eron JJ, Javan AC, Bender Ignacio
R, et al: Safety and efficacy of combination SARS-CoV-2
neutralizing monoclonal antibodies amubarvimab plus romlusevimab in
nonhospitalized patients with COVID-19. Ann Intern Med.
176:658–666. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim
YG, Jeong JH, Kim M, Kim JI, Kim P, et al: A therapeutic
neutralizing antibody targeting receptor binding domain of
SARS-CoV-2 spike protein. Nat Commun. 12:2882021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang YT, Allen RD, Kim K, Shafee N,
Gonzalez AJ, Nguyen MN, Valentine KM, Cao X, Lu L, Pai CI, et al:
SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad
neutralizing activity and No evidence of antibody-dependent
enhancement. Antiviral Res. 195:1051852021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tian D, Sun Y, Xu H and Ye Q: The
emergence and epidemic characteristics of the highly mutated
SARS-CoV-2 Omicron variant. J Med Virol. 94:2376–2383. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo H, Gao Y, Li T, Li T, Lu Y, Zheng L,
Liu Y, Yang T, Luo F, Song S, et al: Structures of Omicron spike
complexes and implications for neutralizing antibody development.
Cell Rep. 39:1107702022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Muyldermans S: Applications of Nanobodies.
Annu Rev Anim Biosci. 9:401–421. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu J, Xu K, Jung S, Conte A, Lieberman J,
Muecksch F, Lorenzi JCC, Park S, Schmidt F, Wang Z, et al:
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2
variants. Nature. 595:278–282. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weiss SR and Navas-Martin S: Coronavirus
pathogenesis and the emerging pathogen severe acute respiratory
syndrome coronavirus. Microbiol Mol Biol Rev. 69:635–664. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song
ZG, Hu Y, Tao ZW, Tian JH, Pei YY, et al: A new coronavirus
associated with human respiratory disease in China. Nature.
579:265–269. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang H and Rao Z: Structural biology of
SARS-CoV-2 and implications for therapeutic development. Nat Rev
Microbiol. 19:685–700. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Y, Liu Q and Guo D: Emerging
coronaviruses: Genome structure, replication, and pathogenesis. J
Med Virol. 92:418–423. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim D, Lee JY, Yang JS, Kim JW, Kim VN and
Chang H: The Architecture of SARS-CoV-2 Transcriptome. Cell.
181:914–921.e10. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell.
181:271–280.e8. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang Y, Yang C, Xu XF, Xu W and Liu SW:
Structural and functional properties of SARS-CoV-2 spike protein:
potential antivirus drug development for COVID-19. Acta Pharmacol
Sin. 41:1141–1149. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Walls AC, Park YJ, Tortorici MA, Wall A,
McGuire AT and Veesler D: Structure, Function, and Antigenicity of
the SARS-CoV-2 Spike Glycoprotein. Cell. 181:281–292.e6. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang Q, Zhang Y, Wu L, Niu S, Song C,
Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, et al: Structural and
Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell.
181:894–904.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cai Y, Zhang J, Xiao T, Peng H, Sterling
SM, Walsh RM Jr, Rawson S, Rits-Volloch S and Chen B: Distinct
conformational states of SARS-CoV-2 spike protein. Science.
369:1586–1592. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Song W, Gui M, Wang X and Xiang Y: Cryo-EM
structure of the SARS coronavirus spike glycoprotein in complex
with its host cell receptor ACE2. PLoS Pathog. 14:e10072362018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chi X, Yan R, Zhang J, Zhang G, Zhang Y,
Hao M, Zhang Z, Fan P, Dong Y, Yang Y, et al: A neutralizing human
antibody binds to the N-terminal domain of the Spike protein of
SARS-CoV-2. Science. 369:650–655. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang
Q, Luo Y, Chan JF, Sahi V, Figueroa A, et al: Potent neutralizing
antibodies against multiple epitopes on SARS-CoV-2 spike. Nature.
584:450–456. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C,
Zhang J, Weng T, Zhang Z, Wu Z, et al: Molecular Architecture of
the SARS-CoV-2 Virus. Cell. 183:730–738.e13. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fantini J, Di Scala C, Chahinian H and
Yahi N: Structural and molecular modelling studies reveal a new
mechanism of action of chloroquine and hydroxychloroquine against
SARS-CoV-2 infection. Int J Antimicrob Agents. 55:1059602020.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fantini J, Chahinian H and Yahi N:
Synergistic antiviral effect of hydroxychloroquine and azithromycin
in combination against SARS-CoV-2: What molecular dynamics studies
of virus-host interactions reveal. Int J Antimicrob Agents.
56:1060202020. View Article : Google Scholar
|
|
53
|
Seyran M, Takayama K, Uversky VN, Adadi P,
Mohamed Abd El-Aziz T, Soares AG, Kandimalla R, Tambuwala M, Hassan
SS, Azad GK, et al: The structural basis of accelerated host cell
entry by SARS-CoV-2†. FEBS J. 288:5010–5020. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S,
Zhang Q, Shi X, Wang Q, Zhang L and Wang X: Structure of the
SARS-CoV-2 spike receptor-binding domain bound to the ACE2
receptor. Nature. 581:215–220. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li F, Li W, Farzan M and Harrison SC:
Structure of SARS coronavirus spike receptor-binding domain
complexed with receptor. Science. 309:1864–1868. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang J, Cai Y, Xiao T, Lu J, Peng H,
Sterling SM, Walsh RM Jr, Rits-Volloch S, Zhu H, Woosley AN, et al:
Structural impact on SARS-CoV-2 spike protein by D614G
substitution. Science. 372:525–530. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jackson CB, Farzan M, Chen B and Choe H:
Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol.
23:3–20. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Benton DJ, Wrobel AG, Xu P, Roustan C,
Martin SR, Rosenthal PB, Skehel JJ and Gamblin SJ: Receptor binding
and priming of the spike protein of SARS-CoV-2 for membrane fusion.
Nature. 588:327–330. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bayati A, Kumar R, Francis V and McPherson
PS: SARS-CoV-2 infects cells after viral entry via
clathrin-mediated endocytosis. J Biol Chem. 296:1003062021.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jaimes JA, Millet JK and Whittaker GR:
Proteolytic Cleavage of the SARS-CoV-2 Spike protein and the role
of the novel S1/S2 Site. iScienc. 23:1012122020. View Article : Google Scholar
|
|
61
|
Newcombe C and Newcombe AR: Antibody
production: Polyclonal-derived biotherapeutics. J Chromatogr B
Analyt Technol Biomed Life Sci. 848:2–7. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ascoli CA and Aggeler B: Overlooked
benefits of using polyclonal antibodies. Biotechniques. 65:127–136.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Leenaars M and Hendriksen CF: Critical
steps in the production of polyclonal and monoclonal antibodies:
Evaluation and recommendations. ILAR J. 46:269–279. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zylberman V, Sanguineti S, Pontoriero AV,
Higa SV, Cerutti ML, Morrone Seijo SM, Pardo R, Muñoz L, Acuña
Intrieri ME, Alzogaray VA, et al: Development of a hyperimmune
equine serum therapy for COVID-19 in Argentina. Medicina (B Aires).
80 (Suppl 3):S1–S6. 2020.
|
|
65
|
Lopardo G, Belloso WH, Nannini E, Colonna
M, Sanguineti S, Zylberman V, Muñoz L, Dobarro M, Lebersztein G,
Farina J, et al: RBD-specific polyclonal F(ab´)2 fragments of
equine antibodies in patients with moderate to severe COVID-19
disease: A randomized, multicenter, double-blind,
placebo-controlled, adaptive phase 2/3 clinical trial.
EClinicalMedicine. 34:1008432021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Vanhove B, Duvaux O, Rousse J, Royer PJ,
Evanno G, Ciron C, Lheriteau E, Vacher L, Gervois N, Oger R, et al:
High neutralizing potency of swine glyco-humanized polyclonal
antibodies against SARS-CoV-2. Eur J Immunol. 51:1412–1422. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gaborit B, Dailly E, Vanhove B, Josien R,
Lacombe K, Dubee V, Ferre V, Brouard S, Ader F, Vibet MA, et al:
Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized
Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate
Pneumonia: A Randomized, Double-Blind, Placebo-Controlled, Phase
IIa Study. Antimicrob Agents Chemother. 65:e01237212021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Vanhove B, Marot S, So RT, Gaborit B,
Evanno G, Malet I, Lafrogne G, Mevel E, Ciron C, Royer PJ, et al:
XAV-19, a swine glyco-humanized polyclonal antibody against
SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes
and broadly neutralizes variants. Front Immunol. 12:7612502021.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Singh R, Chandley P and Rohatgi S: Recent
advances in the development of monoclonal antibodies and
next-generation antibodies. Immunohorizons. 7:886–897. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Safdari Y, Farajnia S, Asgharzadeh M and
Khalili M: Antibody humanization methods-a review and update.
Biotechnol Genet Eng Rev. 29:175–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yu H, Borsotti C, Schickel JN, Zhu S,
Strowig T, Eynon EE, Frleta D, Gurer C, Murphy AJ, Yancopoulos GD,
et al: A novel humanized mouse model with significant improvement
of class-switched, antigen-specific antibody production. Blood.
129:959–969. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Pedrioli A and Oxenius A: Single B cell
technologies for monoclonal antibody discovery. Trends Immunol.
42:1143–1158. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Winter G and Milstein C: Man-made
antibodies. Nature. 349:293–299. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
McCafferty J, Griffiths AD, Winter G and
Chiswell DJ: Phage antibodies: Filamentous phage displaying
antibody variable domains. Nature. 348:552–554. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chen F, Liu Z, Kang W, Jiang F, Yang X,
Yin F, Zhou Z and Li Z: Single-domain antibodies against SARS-CoV-2
RBD from a two-stage phage screening of universal and focused
synthetic libraries. BMC Infect Dis. 24:1992024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Barnes CO, Jette CA, Abernathy ME, Dam KA,
Esswein SR, Gristick HB, Malyutin AG, Sharaf NG, Huey-Tubman KE,
Lee YE, et al: SARS-CoV-2 neutralizing antibody structures inform
therapeutic strategies. Nature. 588:682–687. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Piccoli L, Park YJ, Tortorici MA,
Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto
D, Rosen LE, Bowen JE, et al: Mapping neutralizing and
immunodominant sites on the SARS-CoV-2 spike receptor-binding
domain by structure-guided high-resolution serology. Cell.
183:1024–1042.e21. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Röltgen K, Powell AE, Wirz OF, Stevens BA,
Hogan CA, Najeeb J, Hunter M, Wang H, Sahoo MK, Huang C, et al:
Defining the features and duration of antibody responses to
SARS-CoV-2 infection associated with disease severity and outcome.
Sci Immunol. 5:eabe02402020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Barnes CO, West AP Jr, Huey-Tubman KE,
Hoffmann MAG, Sharaf NG, Hoffman PR, Koranda N, Gristick HB,
Gaebler C, Muecksch F, et al: Structures of Human Antibodies Bound
to SARS-CoV-2 spike reveal common epitopes and recurrent features
of antibodies. Cell. 182:828–842.e16. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wu Y, Wang F, Shen C, Peng W, Li D, Zhao
C, Li Z, Li S, Bi Y, Yang Y, et al: A noncompeting pair of human
neutralizing antibodies block COVID-19 virus binding to its
receptor ACE2. Science. 368:1274–1278. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Shi R, Shan C, Duan X, Chen Z, Liu P, Song
J, Song T, Bi X, Han C, Wu L, et al: A human neutralizing antibody
targets the receptor-binding site of SARS-CoV-2. Nature.
584:120–124. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Banach BB, Cerutti G, Fahad AS, Shen CH,
Oliveira De Souza M, Katsamba PS, Tsybovsky Y, Wang P, Nair MS,
Huang Y, et al: Paired heavy- and light-chain signatures contribute
to potent SARS-CoV-2 neutralization in public antibody responses.
Cell Rep. 37:1097712021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Starr TN, Czudnochowski N, Liu Z, Zatta F,
Park YJ, Addetia A, Pinto D, Beltramello M, Hernandez P, Greaney
AJ, et al: SARS-CoV-2 RBD antibodies that maximize breadth and
resistance to escape. Nature. 597:97–102. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cameroni E, Bowen JE, Rosen LE, Saliba C,
Zepeda SK, Culap K, Pinto D, VanBlargan LA, De Marco A, di Iulio J,
et al: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron
antigenic shift. Nature. 602:664–670. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Brouwer PJM, Caniels TG, van der Straten
K, Snitselaar JL, Aldon Y, Bangaru S, Torres JL, Okba NMA,
Claireaux M, Kerster G, et al: Potent neutralizing antibodies from
COVID-19 patients define multiple targets of vulnerability.
Science. 369:643–650. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kim SI, Noh J, Kim S, Choi Y, Yoo DK, Lee
Y, Lee H, Jung J, Kang CK, Song KH, et al: Stereotypic neutralizing
VH antibodies against SARS-CoV-2 spike protein receptor binding
domain in patients with COVID-19 and healthy individuals. Sci
Transl Med. 13:eabd69902021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Greaney AJ, Starr TN, Barnes CO, Weisblum
Y, Schmidt F, Caskey M, Gaebler C, Cho A, Agudelo M, Finkin S, et
al: Mapping mutations to the SARS-CoV-2 RBD that escape binding by
different classes of antibodies. Nat Commun. 12:41962021.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li D, Edwards RJ, Manne K, Martinez DR,
Schäfer A, Alam SM, Wiehe K, Lu X, Parks R, Sutherland LL, et al:
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing
and neutralizing antibodies. Cell. 184:4203–4219.e32. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tian X, Li C, Huang A, Xia S, Lu S, Shi Z,
Lu L, Jiang S, Yang Z, Wu Y and Ying T: Potent binding of 2019
novel coronavirus spike protein by a SARS coronavirus-specific
human monoclonal antibody. Emerg Microbes Infect. 9:382–385. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
ter Meulen J, van den Brink EN, Poon LL,
Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA,
van Deventer E, et al: Human monoclonal antibody combination
against SARS coronavirus: synergy and coverage of escape mutants.
PLoS Med. 3:e2372006. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv
H, Mok CKP and Wilson IA: A highly conserved cryptic epitope in the
receptor binding domains of SARS-CoV-2 and SARS-CoV. Science.
368:630–633. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Gupta A, Gonzalez-Rojas Y, Juarez E,
Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis J, Zheng H, Scott
N, et al: Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing
Antibody Sotrovimab. N Engl J Med. 385:1941–1950. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Rockett R, Basile K, Maddocks S, Fong W,
Agius JE, Johnson-Mackinnon J, Arnott A, Chandra S, Gall M, Draper
J, et al: Resistance Mutations in SARS-CoV-2 delta variant after
sotrovimab use. N Engl J Med. 386:1477–1479. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Martinez DR, Schaefer A, Gobeil S, Li D,
De la Cruz G, Parks R, Lu X, Barr M, Manne K, Mansouri K, et al: A
broadly neutralizing antibody protects against SARS-CoV,
pre-emergent bat CoVs, and SARS-CoV-2 variants in mice. bioRxiv
(Preprint). doi: 10.1101/2021.04.27.441655.
|
|
95
|
Wec AZ, Wrapp D, Herbert AS, Maurer DP,
Haslwanter D, Sakharkar M, Jangra RK, Dieterle ME, Lilov A, Huang
D, et al: Broad neutralization of SARS-related viruses by human
monoclonal antibodies. Science. 369:731–736. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Rappazzo CG, Tse LV, Kaku CI, Wrapp D,
Sakharkar M, Huang D, Deveau LM, Yockachonis TJ, Herbert AS,
Battles MB, et al: Broad and potent activity against SARS-like
viruses by an engineered human monoclonal antibody. Science.
371:823–829. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Li D, Sempowski GD, Saunders KO, Acharya P
and Haynes BF: SARS-CoV-2 Neutralizing Antibodies for COVID-19
Prevention and Treatment. Annu Rev Med. 73:1–16. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hastie KM, Li H, Bedinger D, Schendel SL,
Dennison SM, Li K, Rayaprolu V, Yu X, Mann C, Zandonatti M, et al:
Defining variant-resistant epitopes targeted by SARS-CoV-2
antibodies: A global consortium study. Science. 374:472–478. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
McCallum M, De Marco A, Lempp FA,
Tortorici MA, Pinto D, Walls AC, Beltramello M, Chen A, Liu Z,
Zatta F, et al: N-terminal domain antigenic mapping reveals a site
of vulnerability for SARS-CoV-2. Cell. 184:2332–2347.e16. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chi XY, Yan RH, Zhang J, Zhang G, Zhang Y,
Hao M, Zhang Z, Fan P, Dong Y, Yang Y, et al: A neutralizing human
antibody binds to the N-terminal domain of the Spike protein of
SARS-CoV-2. Science. 369:650–655. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wrapp D, De Vlieger D, Corbett KS, Torres
GM, Wang N, Van Breedam W, Roose K, van Schie L; VIB-CMB COVID-19
Response Team; Hoffmann M, ; et al: Structural basis for potent
neutralization of betacoronaviruses by single-domain camelid
antibodies. Cell. 181:1436–1441. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hoffmann M, Kleine-Weber H and Pöhlmann S:
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 is
essential for infection of human lung cells. Mol Cell.
78:779–784.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Cerutti G, Guo Y, Zhou T, Gorman J, Lee M,
Rapp M, Reddem ER, Yu J, Bahna F, Bimela J, et al: Potent
SARS-CoV-2 neutralizing antibodies directed against spike
N-terminal domain target a single supersite. Cell Host Microbe.
29:819–833.e7. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Nielsen SCA, Yang F, Jackson KJL, Hoh RA,
Röltgen K, Jean GH, Stevens BA, Lee JY, Rustagi A, Rogers AJ, et
al: Human B Cell Clonal Expansion and Convergent Antibody Responses
to SARS-CoV-2. Cell Host Microbe. 28:516–525.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Boyd SD, Gaëta BA, Jackson KJ, Fire AZ,
Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B, Jones CD, et
al: Individual variation in the germline Ig gene repertoire
inferred from variable region gene rearrangements. J Immunol.
184:6986–6992. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wang N, Sun Y, Feng R, Wang Y, Guo Y,
Zhang L, Deng YQ, Wang L, Cui Z, Cao L, et al: Structure-based
development of human antibody cocktails against SARS-CoV-2. Cell
Res. 31:101–103. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Haslwanter D, Dieterle ME, Wec AZ, O'Brien
CM, Sakharkar M, Florez C, Tong K, Rappazzo CG, Lasso G, Vergnolle
O, et al: A Combination of Receptor-Binding Domain and N-Terminal
Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2
Spike Neutralization-Escape Mutants. mBio. 12:e02473212021.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Nguyen-Contant P, Embong AK, Kanagaiah P,
Chaves FA, Yang H, Branche AR, Topham DJ and Sangster MY: S
Protein-Reactive IgG and Memory B Cell Production after Human
SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
mBio. 11:e01991–20. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Guo L, Wang Y, Kang L, Hu Y, Wang L, Zhong
J, Chen H, Ren L, Gu X, Wang G, et al: Cross-reactive antibody
against human coronavirus OC43 spike protein correlates with
disease severity in COVID-19 patients: A retrospective study. Emerg
Microbes Infect. 10:664–676. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zohar T, Loos C, Fischinger S, Atyeo C,
Wang C, Slein MD, Burke J, Yu J, Feldman J, Hauser BM, et al:
Compromised humoral functional evolution tracks with SARS-CoV-2
Mortality. Cell. 183:1508–1519.e12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Ma X, Zou F, Yu F, Li R, Yuan Y, Zhang Y,
Zhang X, Deng J, Chen T, Song Z, et al: Nanoparticle vaccines based
on the receptor binding Domain (RBD) and Heptad Repeat (HR) of
SARS-CoV-2 elicit robust protective immune responses. Immunity.
53:1315–1330.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Silva RP, Huang Y, Nguyen AW, Hsieh CL,
Olaluwoye OS, Kaoud TS, Wilen RE, Qerqez AN, Park JG, Khalil AM, et
al: Identification of a conserved S2 epitope present on spike
proteins from all highly pathogenic coronaviruses. Elife.
12:e837102023. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Hsieh CL, Werner AP, Leist SR, Stevens LJ,
Falconer E, Goldsmith JA, Chou CW, Abiona OM, West A, Westendorf K,
et al: Stabilized coronavirus spike stem elicits a broadly
protective antibody. Cell Rep. 37:1099292021. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Hamers-Casterman C, Atarhouch T,
Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N and
Hamers R: Naturally occurring antibodies devoid of light chains.
Nature. 363:446–448. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Tanaka Y, Nishikawa M, Kamisaki K, Hachiya
S, Nakamura M, Kuwazuru T, Tanimura S, Soyano K and Takeda K:
Marine-derived microbes and molecules for drug discovery. Inflamm
Regen. 42:182022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Muyldermans S: Nanobodies: Natural
single-domain antibodies. Annu Rev Biochem. 82:775–797. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Jovčevska I and Muyldermans S: The
therapeutic potential of nanobodies. BioDrugs. 34:11–26. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Muyldermans S, Baral TN, Retamozzo VC, De
Baetselier P, De Genst E, Kinne J, Leonhardt H, Magez S, Nguyen VK,
Revets H, et al: Camelid immunoglobulins and nanobody technology.
Vet Immunol Immunopathol. 128:178–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zielonka S, Empting M, Grzeschik J,
Könning D, Barelle CJ and Kolmar H: Structural insights and
biomedical potential of IgNAR scaffolds from sharks. MAbs. 7:15–25.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Transue TR, De Genst E, Ghahroudi MA, Wyns
L and Muyldermans S: Camel single-domain antibody inhibits enzyme
by mimicking carbohydrate substrate. Proteins. 32:515–522. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Bachmann MF, Mohsen MO, Zha L, Vogel M and
Speiser DE: SARS-CoV-2 structural features may explain limited
neutralizing-antibody responses. NPJ Vaccines. 6:22021. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Steeland S, Vandenbroucke RE and Libert C:
Nanobodies as therapeutics: Big opportunities for small antibodies.
Drug Discov Today. 21:1076–1113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Holliger P and Hudson PJ: Engineered
antibody fragments and the rise of single domains. Nat Biotechnol.
23:1126–1136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Vu KB, Ghahroudi MA, Wyns L and
Muyldermans S: Comparison of llama VH sequences from conventional
and heavy chain antibodies. Mol Immunol. 34:1121–1131. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Zhang YF, Sun Y, Hong J and Ho M:
Humanization of the Shark VNAR Single Domain Antibody Using CDR
Grafting. Curr Protoc. 3:e6302023. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Almagro JC and Fransson J: Humanization of
antibodies. Front Biosci. 13:1619–1633. 2008.PubMed/NCBI
|
|
127
|
Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z,
Gu C, Zhang R, Tu C, Xie Y, et al: Identification of Human
Single-Domain Antibodies against SARS-CoV-2. Cell Host Microbe.
27:891–898.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Hassanzadeh-Ghassabeh G, Devoogdt N, De
Pauw P, Vincke C and Muyldermans S: Nanobodies and their potential
applications. Nanomedicine (Lond). 8:1013–1026. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Harmsen MM and De Haard HJ: Properties,
production, and applications of camelid single-domain antibody
fragments. Appl Microbiol Biotechnol. 77:13–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Schoof M, Faust B, Saunders RA, Sangwan S,
Rezelj V, Hoppe N, Boone M, Billesbølle CB, Puchades C, Azumaya CM,
et al: An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by
stabilizing inactive Spike. Science. 370:1473–1479. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Van Heeke G, Allosery K, De Brabandere V,
De Smedt T, Detalle L and de Fougerolles A: Nanobodies®
as inhaled biotherapeutics for lung diseases. Pharmacol Ther.
169:47–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Xiang Y, Nambulli S, Xiao Z, Liu H, Sang
Z, Duprex WP, Schneidman-Duhovny D, Zhang C and Shi Y: Versatile
and multivalent nanobodies efficiently neutralize SARS-CoV-2.
Science. 370:1479–1484. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Nambulli S, Xiang Y, Tilston-Lunel NL,
Rennick LJ, Sang Z, Klimstra WB, Reed DS, Crossland NA, Shi Y and
Duprex WP: Inhalable Nanobody (PiN-21) prevents and treats
SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci
Adv. 7:eabh03192021. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Gai J, Ma L, Li G, Zhu M, Qiao P, Li X,
Zhang H, Zhang Y, Chen Y, Ji W, et al: A potent neutralizing
nanobody against SARS-CoV-2 with inhaled delivery potential.
MedComm (2020). 2:101–113. 2021.PubMed/NCBI
|
|
135
|
Li C, Zhan W, Yang Z, Tu C, Hu G, Zhang X,
Song W, Du S, Zhu Y, Huang K, et al: Broad neutralization of
SARS-CoV-2 variants by an inhalable bispecific single-domain
antibody. Cell. 185:1389–1401.e18. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ma H, Zhang X, Zeng W, Zhou J, Chi X, Chen
S, Zheng P, Wang M, Wu Y, Zhao D, et al: A bispecific nanobody
dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern
and offers substantial protection against Omicron via low-dose
intranasal administration. Cell Discov. 8:1322022. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Wu X, Wang Y, Cheng L, Ni F, Zhu L, Ma S,
Huang B, Ji M, Hu H, Li Y, et al: Short-Term Instantaneous
Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2
Mice Conferred by an Intranasal Nanobody (Nb22). Front Immunol.
13:8654012022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Xiang Y, Huang W, Liu H, Sang Z, Nambulli
S, Tubiana J, Williams KL Jr, Duprex WP, Schneidman-Duhovny D,
Wilson IA, et al: Superimmunity by pan-sarbecovirus nanobodies.
Cell Rep. 39:1110042022. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Nagata K, Utsumi D, Asaka MN, Maeda R,
Shirakawa K, Kazuma Y, Nomura R, Horisawa Y, Yanagida Y, Kawai Y,
et al: Intratracheal trimerized nanobody cocktail administration
suppresses weight loss and prolongs survival of SARS-CoV-2 infected
mice. Commun Med (Lond). 2:1522022. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Maeda R, Fujita J, Konishi Y, Kazuma Y,
Yamazaki H, Anzai I, Watanabe T, Yamaguchi K, Kasai K, Nagata K, et
al: A panel of nanobodies recognizing conserved hidden clefts of
all SARS-CoV-2 spike variants including Omicron. Commun Biol.
5:6692022. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Liu H, Wu L, Liu B, Xu K, Lei W, Deng J,
Rong X, Du P, Wang L, Wang D, et al: Two pan-SARS-CoV-2 nanobodies
and their multivalent derivatives effectively prevent Omicron
infections in mice. Cell Rep Med. 4:1009182023. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Bournazos S, Gupta A and Ravetch JV: The
role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev
Immunol. 20:633–643. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Wang TT, Sewatanon J, Memoli MJ, Wrammert
J, Bournazos S, Bhaumik SK, Pinsky BA, Chokephaibulkit K, Onlamoon
N, Pattanapanyasat K, et al: IgG antibodies to dengue enhanced for
FcγRIIIA binding determine disease severity. Science. 355:395–398.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Iwasaki A and Yang Y: The potential danger
of suboptimal antibody responses in COVID-19. Nat Rev Immunol.
20:339–341. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Ubol S and Halstead SB: How innate immune
mechanisms contribute to antibody-enhanced viral infections. Clin
Vaccine Immunol. 17:1829–1835. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Haynes BF, Corey L, Fernandes P, Gilbert
PB, Hotez PJ, Rao S, Santos MR, Schuitemaker H, Watson M and Arvin
A: Prospects for a safe COVID-19 vaccine. Sci Transl Med.
12:eabe09482020. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Yang Y and Xu F: Evolving understanding of
antibody-dependent enhancement (ADE) of SARS-CoV-2. Front Immunol.
13:10082852022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Wang S, Peng Y, Wang R, Jiao S, Wang M,
Huang W, Shan C, Jiang W, Li Z, Gu C, et al: Characterization of
neutralizing antibody with prophylactic and therapeutic efficacy
against SARS-CoV-2 in rhesus monkeys. Nat Commun. 11:57522020.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Liu Y, Soh WT, Kishikawa JI, Hirose M,
Nakayama EE, Li S, Sasai M, Suzuki T, Tada A, Arakawa A, et al: An
infectivity-enhancing site on the SARS-CoV-2 spike protein targeted
by antibodies. Cell. 184:3452–3466.e18. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Wang Z, Deng T, Zhang Y, Niu W, Nie Q,
Yang S, Liu P, Pei P, Chen L, Li H and Cao B: ACE2 can act as the
secondary receptor in the FcγR-dependent ADE of SARS-CoV-2
infection. iScience. 25:1037202022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Tkaczyk C, Okayama Y, Woolhiser MR,
Hagaman DD, Gilfillan AM and Metcalfe DD: Activation of human mast
cells through the high affinity IgG receptor. Mol Immunol.
38:1289–1293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Darrell DO, Gherlone N, Fremont-Smith P,
Tisdall P and Fremont-Smith M: Kawasaki Disease, Multisystem
Inflammatory Syndrome in Children: Antibody-Induced Mast Cell
Activation Hypothesis. J Pediatrics & Pediatr Med. 4:1–7. 2020.
View Article : Google Scholar
|
|
153
|
Ricke DO: Two Different Antibody-Dependent
Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Front Immunol.
12:6400932021. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Yahi N, Chahinian H and Fantini J:
Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the
original Wuhan/D614G strain and Delta variants. A potential risk
for mass vaccination? J Infect. 83:607–635. 2021.PubMed/NCBI
|
|
155
|
Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva
IT, Li C, Wu Y, Jiang Q, Liu Z, et al: Enhancement versus
neutralization by SARS-CoV-2 antibodies from a convalescent donor
associates with distinct epitopes on the RBD. Cell Rep.
34:1086992021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Hachmann NP, Miller J, Collier AY, Ventura
JD, Yu J, Rowe M, Bondzie EA, Powers O, Surve N, Hall K and Barouch
DH: Neutralization Escape by SARS-CoV-2 Omicron Subvariants
BA.2.12.1, BA.4, and BA.5. N Engl J Med. 387:86–88. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Jiang XL, Zhu KL, Wang XJ, Wang GL, Li YK,
He XJ, Sun WK, Huang PX, Zhang JZ, Gao HX, et al: Omicron BQ.1 and
BQ.1.1 escape neutralisation by omicron subvariant breakthrough
infection. Lancet Infect Dis. 23:28–30. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Cao Y, Jian F, Wang J, Yu Y, Song W,
Yisimayi A, Wang J, An R, Chen X, Zhang N, et al: Imprinted
SARS-CoV-2 humoral immunity induces convergent Omicron RBD
evolution. Nature. 614:521–529. 2023.PubMed/NCBI
|
|
159
|
Röltgen K, Nielsen SCA, Silva O, Younes
SF, Zaslavsky M, Costales C, Yang F, Wirz OF, Solis D, Hoh RA, et
al: Immune imprinting, breadth of variant recognition, and germinal
center response in human SARS-CoV-2 infection and vaccination.
Cell. 185:1025–1040.e14. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Liu L, Iketani S, Guo Y, Chan JF, Wang M,
Liu L, Luo Y, Chu H, Huang Y, Nair MS, et al: Striking antibody
evasion manifested by the Omicron variant of SARS-CoV-2. Nature.
602:676–681. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Yang X, Duan H, Liu X, Zhang X, Pan S,
Zhang F, Gao P, Liu B, Yang J, Chi X and Yang W: Broad sarbecovirus
neutralizing antibodies obtained by computational design and
synthetic library screening. J Virol. 97:e00610232023. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Cao Y, Jian F, Zhang Z, Yisimayi A, Hao X,
Bao L, Yuan F, Yu Y, Du S, Wang J, et al: Rational identification
of potent and broad sarbecovirus-neutralizing antibody cocktails
from SARS convalescents. Cell Rep. 41:1118452022. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Ma H, Zhang X, Zheng P, Dube PH, Zeng W,
Chen S, Cheng Q, Yang Y, Wu Y, Zhou J, et al: Hetero-bivalent
nanobodies provide broad-spectrum protection against SARS-CoV-2
variants of concern including Omicron. Cell Res. 32:831–842. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Mendon N, Ganie RA, Kesarwani S, Dileep D,
Sasi S, Lama P, Chandra A and Sirajuddin M: Nanobody derived using
a peptide epitope from the spike protein receptor-binding motif
inhibits entry of SARS-CoV-2 variants. J Biol Chem. 299:1027322023.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Ettich J, Werner J, Weitz HT, Mueller E,
Schwarzer R, Lang PA, Scheller J and Moll JM: A Hybrid Soluble
gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks
Interleukin-6 trans-Signaling and Cellular Infection with
SARS-CoV-2. J Virol. 96:e01622212022. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Lyu X, Imai S, Yamano T and Hanayama R:
Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β
Conjugated Exosomes. Pharm Res. 40:927–935. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Gruell H, Vanshylla K, Weber T, Barnes CO,
Kreer C and Klein F: Antibody-mediated neutralization of
SARS-CoV-2. Immunity. 55:925–944. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Suryadevara N, Shrihari S, Gilchuk P,
VanBlargan LA, Binshtein E, Zost SJ, Nargi RS, Sutton RE, Winkler
ES, Chen EC, et al: Neutralizing and protective human monoclonal
antibodies recognizing the N-terminal domain of the SARS-CoV-2
spike protein. Cell. 184:2316–2331.e15. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Voss WN, Hou YJ, Johnson NV, Delidakis G,
Kim JE, Javanmardi K, Horton AP, Bartzoka F, Paresi CJ, Tanno Y, et
al: Prevalent, protective, and convergent IgG recognition of
SARS-CoV-2 non-RBD spike epitopes. Science. 372:1108–1112. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Cerutti G, Guo Y, Wang P, Nair MS, Huang
Y, Yu J, Liu L, Katsamba PS, Bahna F, Reddem ER, et al:
Neutralizing antibody 5–7 defines a distinct site of vulnerability
in SARS-CoV-2 spike N-terminal domain. Cell Rep. 37:1099282021.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Graham C, Seow J, Huettner I, Khan H,
Kouphou N, Acors S, Winstone H, Pickering S, Galao RP, Dupont L, et
al: Neutralization potency of monoclonal antibodies recognizing
dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted
by the B.1.1.7 variant. Immunity. 54:1276–1289.e6. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Wang Z, Muecksch F, Cho A, Gaebler C,
Hoffmann HH, Ramos V, Zong S, Cipolla M, Johnson B, Schmidt F, et
al: Analysis of memory B cells identifies conserved neutralizing
epitopes on the N-terminal domain of variant SARS-Cov-2 spike
proteins. Immunity. 55:998–1012.e8. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Pinto D, Sauer MM, Czudnochowski N, Low
JS, Tortorici MA, Housley MP, Noack J, Walls AC, Bowen JE, Guarino
B, et al: Broad betacoronavirus neutralization by a stem
helix-specific human antibody. Science. 373:1109–1116. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Zhou P, Yuan M, Song G, Beutler N,
Shaabani N, Huang D, He WT, Zhu X, Callaghan S, Yong P, et al: A
human antibody reveals a conserved site on beta-coronavirus spike
proteins and confers protection against SARS-CoV-2 infection. Sci
Transl Med. 14:eabi92152022. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Shi W, Wang L, Zhou T, Sastry M, Yang ES,
Zhang Y, Chen M, Chen X, Choe M, Creanga A, et al: Vaccine-elicited
murine antibody WS6 neutralizes diverse beta-coronaviruses by
recognizing a helical stem supersite of vulnerability. Structure.
30:1233–1244.e7. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Li W, Chen Y, Prévost J, Ullah I, Lu M,
Gong SY, Tauzin A, Gasser R, Vézina D, Anand SP and Goyette G:
Structural basis and mode of action for two broadly neutralizing
antibodies against SARS-CoV-2 emerging variants of concern. Cell
Rep. 38:1102102022. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Dacon C, Tucker C, Peng L, Lee CD, Lin TH,
Yuan M, Cong Y, Wang L, Purser L, Williams JK, et al: Broadly
neutralizing antibodies target the coronavirus fusion peptide.
Science. 377:728–735. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Low JS, Jerak J, Tortorici MA, McCallum M,
Pinto D, Cassotta A, Foglierini M, Mele F, Abdelnabi R, Weynand B,
et al: ACE2-binding exposes the SARS-CoV-2 fusion peptide to
broadly neutralizing coronavirus antibodies. Science. 377:735–742.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Sun X, Yi C, Zhu Y, Ding L, Xia S, Chen X,
Liu M, Gu C, Lu X, Fu Y, et al: Neutralization mechanism of a human
antibody with pan-coronavirus reactivity including SARS-CoV-2. Nat
Microbiol. 7:1063–1074. 2022. View Article : Google Scholar : PubMed/NCBI
|
